444 related articles for article (PubMed ID: 35740570)
1. Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue.
Munir MU
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740570
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
Lu T; Prakash J
Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Tumor Penetration of Nanomedicines.
Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
[TBL] [Abstract][Full Text] [Related]
4. Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery.
Zhang B; Hu Y; Pang Z
Front Pharmacol; 2017; 8():952. PubMed ID: 29311946
[TBL] [Abstract][Full Text] [Related]
5. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles.
Souri M; Soltani M; Moradi Kashkooli F; Kiani Shahvandi M
J Control Release; 2022 Jan; 341():227-246. PubMed ID: 34822909
[TBL] [Abstract][Full Text] [Related]
6. Strategies to improve tumor penetration of nanomedicines through nanoparticle design.
Zhang YR; Lin R; Li HJ; He WL; Du JZ; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1519. PubMed ID: 29659166
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of Nanomedicine in Tumor Spheroid as an
Roy SM; Garg V; Barman S; Ghosh C; Maity AR; Ghosh SK
Front Bioeng Biotechnol; 2021; 9():785937. PubMed ID: 34926430
[TBL] [Abstract][Full Text] [Related]
8. Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives.
Shen X; Pan D; Gong Q; Gu Z; Luo K
Bioact Mater; 2024 Feb; 32():445-472. PubMed ID: 37965242
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment and nanotherapeutics: intruding the tumor fort.
Ravi Kiran AVVV; Kusuma Kumari G; Krishnamurthy PT; Khaydarov RR
Biomater Sci; 2021 Nov; 9(23):7667-7704. PubMed ID: 34673853
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers.
Yang H; Tong Z; Sun S; Mao Z
J Control Release; 2020 Dec; 328():28-44. PubMed ID: 32858072
[TBL] [Abstract][Full Text] [Related]
13. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
15. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
Overchuk M; Zheng G
Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
[TBL] [Abstract][Full Text] [Related]
16. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
17. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
18. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
19. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
20. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
